3 research outputs found
Additional file 2: Table S1. of Sepsis prediction in critically ill patients by platelet activation markers on ICU admission: a prospective pilot study
Baseline clinical characteristics of study patients (n=99). Table S2. Baseline and 48-h biological characteristics of study patients (n=99). Table S3. Comparison of ICU- and hospital-related characteristics of patients with and without sepsis. (PDF 157 kb
Additional file 1: Figure S1. of Sepsis prediction in critically ill patients by platelet activation markers on ICU admission: a prospective pilot study
Follow-up and sepsis occurrence. Timeline of samplings. Figure S2. Serial measurements of platelet markers and d-dimers for patients who developed sepsis. (DOCX 49 kb
Table_1_Progressive fibrosing interstitial lung disease in rheumatoid arthritis: A retrospective study.DOCX
Background and objectiveRheumatoid arthritis associated-interstitial lung disease (RA-ILD) is the most common pulmonary manifestation of rheumatoid arthritis (RA) and an important cause of mortality. In patients suffering from interstitial lung diseases (ILD) from different etiologies (including RA-ILD), a significant proportion is exhibiting a fibrotic progression despite immunosuppressive therapies, defined as progressive fibrosing interstitial lung disease (PF-ILD). Here, we report the frequency of RA-ILD and PF-ILD in all RA patients’ cohort at University Hospital of Liège and compare their characteristics and outcomes.MethodsPatients were retrospectively recruited from 2010 to 2020. PF-ILD was defined based on functional, clinical and/or iconographic progression criteria within 24 months despite specific anti-RA treatment.ResultsOut of 1,500 RA patients, about one third had high-resolution computed tomography (HRCT) performed, 89 showed RA-ILD and 48 PF-ILD. RA-ILD patients were significantly older than other RA patients (71 old of median age vs. 65, p ConclusionWe identified a prevalence of PF-ILD of 3% in a general RA population. The PF-ILD cohort did not seem to be different in terms of demographic characteristics and mortality compared to RA-ILD patients who did not exhibit the progressive phenotype yet.</p